Emergent Biosolutions
(EBS)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Sales | 704,100 | 329,000 | 397,500 | 343,000 | 583,000 |
| Cost of Goods | 203,500 | 217,500 | 227,800 | 99,300 | 197,100 |
| Gross Profit | 500,600 | 111,500 | 169,700 | 243,700 | 385,900 |
| Operating Expenses | 234,900 | 146,700 | 156,000 | 148,600 | 127,900 |
| Operating Income | 266,200 | -34,700 | 14,500 | 95,400 | 258,100 |
| Interest Expense | 9,000 | 8,400 | 8,600 | 8,500 | 8,700 |
| Other Income | -900 | -2,400 | 1,300 | -1,700 | 3,400 |
| Pre-tax Income | 256,300 | -45,500 | 7,200 | 85,200 | 252,800 |
| Income Tax | 78,400 | -12,800 | 2,600 | 15,500 | 67,400 |
| Net Income Continuous | 177,900 | -32,700 | 4,600 | 69,700 | 185,400 |
| Net Income | $177,900 | $-32,700 | $4,600 | $69,700 | $185,400 |
| EPS Basic Total Ops | 3.31 | -0.61 | 0.09 | 1.31 | 3.52 |
| EPS Basic Continuous Ops | 3.32 | -0.61 | 0.09 | 1.31 | 3.52 |
| EPS Diluted Total Ops | 3.30 | -0.61 | 0.09 | 1.28 | 3.45 |
| EPS Diluted Continuous Ops | 3.30 | -0.61 | 0.09 | 1.28 | 3.45 |
| EBITDA(a) | $338,100 | $-900 | $48,700 | $125,100 | $288,100 |